ASTar in the clinic
ASTar automates antimicrobial susceptibility testing to provide faster results for patient treatment.
qlinea.comCrawled Nov 17, 2026
ASTar automates antimicrobial susceptibility testing to provide faster results for patient treatment.
Antimicrobial resistance threatens the treatment of bloodstream infections and sepsis.
ASTar automates antimicrobial susceptibility testing as a fast and reliable complement to lab routines.
Q-linea is on a mission to improve sepsis treatment and safeguard the effectiveness of antibiotics for generations to come.
A word from Q-linea’s CEO: Stuart Gander
Q-lineaʻs fully automated AST system, ASTar, cuts the diagnostic time by half, not only saving lives but preventing the spread of antimicrobial resistance
Q-lineaʻs fully automated AST system, ASTar, cuts the diagnostic time by half, not only saving lives but preventing the spread of antimicrobial resistance
Q-linea publishes a study showing that leftover bacterial suspension from ASTar® testing can be reused to identify pathogens and detect resistance markers. The workflow integrates rapid antimicrobial susceptibility testing with additional diagnostics, potentially cutting hands-on time and costs versus traditional methods.
The U.S. government accelerates deployment of an expanded **ASTar®** diagnostic panel, a molecular testing tool for infectious diseases. The initiative aims to enhance early detection capabilities across public health systems. No specific implementation details or partners are disclosed in the interim report.
Q-linea AB introduces the ASTar Research Use Only (RUO) Isolate Gram-negative (G-) kit, targeting researchers for early-stage projects. The product aims to gather user feedback to inform future development. Availability is limited to select customers.
Q-linea AB appoints Malin Svensson as Chief Financial Officer and Investor Relations manager. She will join the company no later than January 1, 2027, overseeing financial strategy and stakeholder communications. Svensson’s role expands Q-linea’s leadership team amid growth initiatives.
Q-linea secures a contract role with Premier, Inc., a leading national group purchasing organization. The agreement positions Q-linea to collaborate with Premier’s network of healthcare providers and suppliers. The contract highlights Q-linea’s capabilities in delivering solutions for procurement and operational efficiency in the healthcare sector.
Q-linea secures a contract with a major U.S. health system in the Mid-Atlantic region to deploy its **ASTar®** rapid antimicrobial susceptibility testing (AST) system. The agreement marks the company’s expansion into the U.S. market, leveraging its technology to improve infection diagnosis and treatment efficiency in clinical settings. ASTar® enables faster identification of antibiotic-resistant bacteria, addressing critical needs in hospital laboratories.
Q-linea secures FDA 510(k) clearance for its expanded **ASTar Gram-negative Blood Culture** testing menu under the **ASTar** brand. The approval allows the company to offer an extended range of blood culture tests for detecting Gram-negative bacterial infections. This follows Q-linea’s focus on rapid diagnostic solutions for infectious diseases.